Results 11 to 20 of about 72,161 (311)

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

Cardiovascular Diabetology, 2022
Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin ...
M. Nauck, D. D’Alessio
semanticscholar   +1 more source

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages

Clinical Diabetes, 2023
Unexpected drug shortages of the long-acting glucagon-like peptide-1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist tirzepatide emerged in late 2022 and have ...
Heather P. Whitley, Jennifer M. Trujillo, Joshua J. Neumiller   +2 more
semanticscholar   +1 more source

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis

Diabetologia, 2022
Tirzepatide is a novel dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) currently under review for marketing approval.
T. Karagiannis, Ioannis Avgerinos, A. Liakos, S. Del Prato, D. Matthews, A. Tsapas, E. Bekiari   +6 more
semanticscholar   +1 more source

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

Cell Metabolism, 2021
Summary Uncertainty exists as to whether the glucose-dependent insulinotropic polypeptide receptor (GIPR) should be activated or inhibited for the treatment of obesity. Gipr was recently demonstrated in hypothalamic feeding centers, but the physiological
Qian Zhang, Challa Tenagne Delessa, R. Augustin, Mostafa Bakhti, G. Colldén, D. Drucker, A. Feuchtinger, C. Cáceres, Gerald Grandl, A. Harger, S. Herzig, S. Hofmann, C. Holleman, M. Jastroch, S. Keipert, M. Kleinert, P. Knerr, Konxhe Kulaj, B. Legutko, H. Lickert, Xue Liu, G. Luippold, D. Lutter, Emilija Malogajski, Marta Tarquis Medina, Stephanie A. Mowery, A. Blutke, D. Perez-Tilve, Ciro Salinno, Laura Sehrer, R. DiMarchi, M. Tschöp, K. Stemmer, Brian Finan, C. Wolfrum, T. Müller   +35 more
semanticscholar   +1 more source

GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells.

European Journal of Endocrinology, 2023
OBJECTIVE Drugs targeting the glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) are emerging as treatments for type-2 diabetes and obesity.
Morten S. Hansen, K. Søe, L. L. Christensen, Paula Fernandez-Guerra, N. W. Hansen, R. Wyatt, C. Martin, R. Hardy, T. L. Andersen, J. B. Olesen, B. Hartmann, M. Rosenkilde, M. Kassem, Alexander Rauch, C. Gorvin, M. Frost   +15 more
semanticscholar   +1 more source

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

JCI Insight, 2020
Tirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis.
F. Willard, J. Douros, M. Gabe, A. D. Showalter, D. B. Wainscott, T. Suter, M. Capozzi, W. J. C. van der Velden, Cynthia Stutsman, G. Cardona, S. Urva, P. Emmerson, J. Holst, D. D’Alessio, M. Coghlan, M. Rosenkilde, Jonathan E. Campbell, K. Sloop   +17 more
semanticscholar   +1 more source

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells

Science Advances, 2021
GIPR activity in α cells is required for the complete metabolic response to a meal. Glucose-dependent insulinotropic polypeptide (GIP) communicates nutrient intake from the gut to islets, enabling optimal levels of insulin secretion via the GIP receptor (
K. El, S. Gray, M. Capozzi, E. Knuth, E. Jin, B. Svendsen, A. Clifford, J. L. Brown, S. Encisco, B. M. Chazotte, K. Sloop, D. J. Nunez, M. Merrins, D. D’Alessio, J. E. Campbell   +14 more
semanticscholar   +1 more source

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity

Frontiers in Endocrinology, 2022
Incretin-based therapies with glucagon-like peptide-1 receptor agonists (GLP-1RA) are already established in the treatment of type 2 diabetes (T2D). The development of novel dual- or triple-receptor agonists that bind to the receptors not only for GLP-1 ...
B. Gallwitz
semanticscholar   +1 more source

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect

Cardiovascular Diabetology, 2021
Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
E. Fisman, A. Tenenbaum
semanticscholar   +1 more source

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes

Journal of Clinical Endocrinology and Metabolism, 2020
Context Novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA ...
Melissa K Thomas, Amir Nikooienejad, R. Bray, Xuewei Cui, J. Wilson, K. Duffin, Z. Milicevic, A. Haupt, D. Robins   +8 more
semanticscholar   +1 more source